A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: tucatinib|DRUG: capecitabine|DRUG: trastuzumab|DRUG: placebo
Sponsor: Seagen Inc.